SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $43

HC Wainwright & Co. maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and raises the price target from $40 to $43.

Benzinga · 03/02/2020 17:11

HC Wainwright & Co. maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and raises the price target from $40 to $43.